[1. Chen, ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001; 18: 1645-50.10.1023/A:1013319408893]Open DOISearch in Google Scholar
[2. Raw AS, Furness MS, Gill DS, Adams RC, Holcombe FO, Yu LX. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv Drug Deliv Rev. 2004; 56:397-414.10.1016/j.addr.2003.10.01114962589]Search in Google Scholar
[3. WHO Tech Rep Ser. Additional guidelines for organizations performing in vivo bioequivalence studies. Geneva 2006.]Search in Google Scholar
[4. Jullangkoon, M, Jarurathanasirikul S, Ainlang N. Bioequivalence study of cefepime intramuscular injection in healthy volunteers. Asian Biomed. 2014; 8: 237-4010.5372/1905-7415.0802.284]Search in Google Scholar